Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

Cell Reports

Volumn 14, Issue 10, 2016, Pages 2490-2501

  Campbell, James ^a   Ryan, Colm J ^b   Brough, Rachel ^a   Bajrami, Ilirjana ^a   Pemberton, Helen N ^a   Chong, Irene Y ^a,c   Costa Cabral, Sara ^a   Frankum, Jessica ^a   Gulati, Aditi ^a   Holme, Harriet ^a,d   Miller, Rowan ^a,d   Postel Vinay, Sophie ^a,e   Rafiq, Rumana ^a   Wei, Wenbin ^a   Williamson, Chris T ^a   Quigley, David A ^f   Tym, Joe ^a   Al Lazikani, Bissan ^a   Fenton, Timothy ^d   Natrajan, Rachael ^a   Strauss, Sandra J ^d   Ashworth, Alan ^a,f   Lord, Christopher J ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; AZD 4547; FIBROBLAST GROWTH FACTOR RECEPTOR 4; PROTEIN KINASE; SMAD4 PROTEIN; SMALL INTERFERING RNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ARTICLE; AURKA GENNE; BREAST CANCER; CANCER CELL LINE; CDK11A GENE; CENTRAL NERVOUS SYSTEM TUMOR; CHEK1 GENE; CHEMOSENSITIVITY; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GENE; GENE MUTATION; GENETIC SCREENING; GUCY2D GENE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG CANCER; ONCOGENE; OSTEOSARCOMA; OSTEOSARCOMA CELL; OVARY CANCER; PANCREAS CANCER; PLK1 GENE; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; UTERINE CERVIX CANCER; WEE1 GENE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MUTATION; NEOPLASMS; PROTEIN KINASES; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SMAD4 PROTEIN;

EID: 84960407495     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.02.023     Document Type: Article

References (76)

1. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. ToGA Trial Investigators.
2. Bansal R., Magge S., Winkler S. Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells. J. Neurosci. Res. 2003, 74:486-493.
3. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
4. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
5. Belham C., Roig J., Caldwell J.A., Aoyama Y., Kemp B.E., Comb M., Avruch J. A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J. Biol. Chem. 2003, 278:34897-34909.
6. Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc., B 1995, 57:289-300.
7. Berriz G.F., Beaver J.E., Cenik C., Tasan M., Roth F.P. Next generation software for functional trend analysis. Bioinformatics 2009, 25:3043-3044.
8. Beyer A., Bandyopadhyay S., Ideker T. Integrating physical and genetic maps: from genomes to interaction networks. Nat. Rev. Genet. 2007, 8:699-710.
9. Boutros M., Brás L.P., Huber W. Analysis of cell-based RNAi screens. Genome Biol. 2006, 7:R66.
10. Brough R., Frankum J.R., Sims D., Mackay A., Mendes-Pereira A.M., Bajrami I., Costa-Cabral S., Rafiq R., Ahmad A.S., Cerone M.A., et al. Functional viability profiles of breast cancer. Cancer Discov. 2011, 1:260-273.
11. Casado P., Alcolea M.P., Iorio F., Rodríguez-Prados J.C., Vanhaesebroeck B., Saez-Rodriguez J., Joel S., Cutillas P.R. Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol. 2013, 14:R37.
12. Cerami E.G., Gross B.E., Demir E., Rodchenkov I., Babur O., Anwar N., Schultz N., Bader G.D., Sander C. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res. 2011, 39:D685-D690.
13. Chatr-Aryamontri A., Breitkreutz B.J., Oughtred R., Boucher L., Heinicke S., Chen D., Stark C., Breitkreutz A., Kolas N., O'Donnell L., et al. The BioGRID interaction database: 2015 update. Nucleic Acids Res. 2015, 43:D470-D478.
14. Chen Y.W., Hsiao P.J., Weng C.C., Kuo K.K., Kuo T.L., Wu D.C., Hung W.C., Cheng K.H. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells. BMC Cancer 2014, 14:181.
15. Cheng F., Jia P., Wang Q., Zhao Z. Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget 2014, 5:3697-3710.
16. Collins S.R., Miller K.M., Maas N.L., Roguev A., Fillingham J., Chu C.S., Schuldiner M., Gebbia M., Recht J., Shales M., et al. Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 2007, 446:806-810.
17. Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 2014, 1:140035.
18. Creixell P., Schoof E.M., Simpson C.D., Longden J., Miller C.J., Lou H.J., Perryman L., Cox T.R., Zivanovic N., Palmeri A., et al. Kinome-wide decoding of network-attacking mutations rewiring cancer signaling. Cell 2015, 163:202-217.
19. Das J., Yu H. HINT: High-quality protein interactomes and their applications in understanding human disease. BMC Syst. Biol. 2012, 6:92.
20. Dérijard B., Raingeaud J., Barrett T., Wu I.H., Han J., Ulevitch R.J., Davis R.J. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995, 267:682-685.
21. Dulak A.M., Stojanov P., Peng S., Lawrence M.S., Fox C., Stewart C., Bandla S., Imamura Y., Schumacher S.E., Shefler E., et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 2013, 45:478-486.
22. Fiedler D., Braberg H., Mehta M., Chechik G., Cagney G., Mukherjee P., Silva A.C., Shales M., Collins S.R., van Wageningen S., et al. Functional organization of the S. cerevisiae phosphorylation network. Cell 2009, 136:952-963.
23. Forbes S.A., Beare D., Gunasekaran P., Leung K., Bindal N., Boutselakis H., Ding M., Bamford S., Cole C., Ward S., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015, 43:D805-D811.
24. Franceschini A., Szklarczyk D., Frankild S., Kuhn M., Simonovic M., Roth A., Lin J., Minguez P., Bork P., von Mering C., Jensen L.J. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41:D808-D815.
25. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
26. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
27. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell 2013, 153:17-37.
28. Gavine P.R., Mooney L., Kilgour E., Thomas A.P., Al-Kadhimi K., Beck S., Rooney C., Coleman T., Baker D., Mellor M.J., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012, 72:2045-2056.
29. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
30. Grueneberg D.A., Li W., Davies J.E., Sawyer J., Pearlberg J., Harlow E. Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc. Natl. Acad. Sci. USA 2008, 105:16490-16495.
31. Hagberg, A., Schult, D., and Swart, P. (2008). Exploring network structure, dynamics, and function using NetworkX. G. Varoquaux, T. Vaught, and J. Millman, eds. Proceedings of the 7th Python in Science Conference, 11-16.
32. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353.
33. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10:262-267.
34. Hornbeck P.V., Zhang B., Murray B., Kornhauser J.M., Latham V., Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015, 43:D512-D520.
35. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 2010, 9:57-67.
36. Jones R.B., Gordus A., Krall J.A., MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006, 439:168-174.
37. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5:689-698.
38. Kansara M., Teng M.W., Smyth M.J., Thomas D.M. Translational biology of osteosarcoma. Nat. Rev. Cancer 2014, 14:722-735.
39. Kelley R., Ideker T. Systematic interpretation of genetic interactions using protein networks. Nat. Biotechnol. 2005, 23:561-566.
40. Koh J.L., Brown K.R., Sayad A., Kasimer D., Ketela T., Moffat J. COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines. Nucleic Acids Res. 2012, 40:D957-D963.
41. Krogan N.J., Lippman S., Agard D.A., Ashworth A., Ideker T. The cancer cell map initiative: defining the hallmark networks of cancer. Mol. Cell 2015, 58:690-698.
42. Lachmann A., Ma'ayan A. KEA: kinase enrichment analysis. Bioinformatics 2009, 25:684-686.
43. Lawrence R.T., Perez E.M., Hernández D., Miller C.P., Haas K.M., Irie H.Y., Lee S.I., Blau C.A., Villén J. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015, 11:630-644.
44. Lizcano J.M., Göransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Mäkelä T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
45. Loijens J.C., Anderson R.A. Type I phosphatidylinositol-4-phosphate 5-kinases are distinct members of this novel lipid kinase family. J. Biol. Chem. 1996, 271:32937-32943.
46. Lord C.J., Tutt A.N., Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 2015, 66:455-470.
47. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
48. Madaule P., Eda M., Watanabe N., Fujisawa K., Matsuoka T., Bito H., Ishizaki T., Narumiya S. Role of citron kinase as a target of the small GTPase Rho in cytokinesis. Nature 1998, 394:491-494.
49. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
50. Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L., et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2012, 2:172-189.
51. Miller T.W., Rexer B.N., Garrett J.T., Arteaga C.L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011, 13:224.
52. Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 2013, 4:609-620.
53. Nath-Sain S., Marignani P.A. LKB1 catalytic activity contributes to estrogen receptor alpha signaling. Mol. Biol. Cell 2009, 20:2785-2795.
54. Pivovarova A.V., Chebotareva N.A., Kremneva E.V., Lappalainen P., Levitsky D.I. Effects of actin-binding proteins on the thermal stability of monomeric actin. Biochemistry 2013, 52:152-160.
55. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
56. Puyol M., Martín A., Dubus P., Mulero F., Pizcueta P., Khan G., Guerra C., Santamaría D., Barbacid M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
57. Rahman S., Sowa M.E., Ottinger M., Smith J.A., Shi Y., Harper J.W., Howley P.M. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. 2011, 31:2641-2652.
58. Ryan C.J., Roguev A., Patrick K., Xu J., Jahari H., Tong Z., Beltrao P., Shales M., Qu H., Collins S.R., et al. Hierarchical modularity and the evolution of genetic interactomes across species. Mol. Cell 2012, 46:691-704.
59. Sadasivam S., DeCaprio J.A. The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat. Rev. Cancer 2013, 13:585-595.
60. Sakharkar M.K., Sakharkar K.R. Targetability of human disease genes. Curr. Drug Discov. Technol. 2007, 4:48-58.
61. Sander J.D., Joung J.K. CRISPR-Cas systems for editing, regulating, and targeting genomes. Nat. Biotechnol. 2014, 32:347-355.
62. Sears R., Nuckolls F., Haura E., Taya Y., Tamai K., Nevins J.R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000, 14:2501-2514.
63. So J., Pasculescu A., Dai A.Y., Williton K., James A., Nguyen V., Creixell P., Schoof E.M., Sinclair J., Barrios-Rodiles M., et al. Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy. Sci. Signal. 2015, 8:rs3.
64. Su N., Du X., Chen L. FGF signaling: its role in bone development and human skeleton diseases. Front. Biosci. 2008, 13:2842-2865.
65. Terfve C., Saez-Rodriguez J. Modeling signaling networks using high-throughput phospho-proteomics. Adv. Exp. Med. Biol. 2012, 736:19-57.
66. Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., Overhauser J., Willson J.K., Markowitz S., Hamilton S.R., Kern S.E., et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 1996, 13:343-346.
67. Tischler J., Lehner B., Fraser A.G. Evolutionary plasticity of genetic interaction networks. Nat. Genet. 2008, 40:390-391.
68. Van Rompay A.R., Norda A., Lindén K., Johansson M., Karlsson A. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol. Pharmacol. 2001, 59:1181-1186.
69. Varjosalo M., Keskitalo S., Van Drogen A., Nurkkala H., Vichalkovski A., Aebersold R., Gstaiger M. The protein interaction landscape of the human CMGC kinase group. Cell Rep. 2013, 3:1306-1320.
70. Voets E., Wolthuis R.M. MASTL is the human orthologue of Greatwall kinase that facilitates mitotic entry, anaphase, and cytokinesis. Cell Cycle 2010, 9:3591-3601.
71. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
72. Workman P., Al-Lazikani B. Drugging cancer genomes. Nat. Rev. Drug Discov. 2013, 12:889-890.
73. Yaffe M.B. The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. Sci. Signal. 2013, 6:pe13.
74. Zeller K.I., Zhao X., Lee C.W., Chiu K.P., Yao F., Yustein J.T., Ooi H.S., Orlov Y.L., Shahab A., Yong H.C., et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc. Natl. Acad. Sci. USA 2006, 103:17834-17839.
75. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.
76. Zhang B., Zhang B., Chen X., Bae S., Singh K., Washington M.K., Datta P.K. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br. J. Cancer 2014, 110:946-957.